Curriculum Vitae
Dr. Fu PENG, Associate Profressor
Email ：fujing126@yeah.net
Affiliation: Department of Pharmacology,
West China School of Pharmacy, Sichuan University
, Chengdu, 610041
Dr. Peng is graduated from the University of Hong Kong and is an associated professor at Sichuan University. The main proposal and study conducted by her is based on the pharmacology of natural products. Dr. Peng is the deputy editor-in-chief of Pharmacology (Bilingual) and the youth editor of China Journal of Traditional Chinese Medicine and Pharmacy. The corresponding study results in more than 50 SCI papers, 6 patents, and 2 awards at the provincial and ministerial level.
Academic fields: Natural Science-Cancer Pharmacology;Study on Genuine medicinal materials from Sichuan
ACADEMIC QUALIFICATIONS
2011-2014 Sichuan University, Bachelor Degree-
-7/16/2012-7/20/2012 Lanzhou University, National Biology Form -11/6/2012-11/16/2012 Fengjia University, Taiwan, Camping for the Excellent Students from Mainland
-8/05/2013-9/13/2013 University of California, Los Angeles
2014-2018 The University of Hong Kong, PhD Degree-
-07/03/2015 -08/03/2015 Hong Kong, Poster Presentation, Tenth International Symposium on Healthy Aging "A Decade of Positive Aging"
-17/08/2015 -20/08/2015 Canada, London ON, Oral Presentation, 14th
Meeting of the Consortium for Globalization of Chinese Medicine
2018-present Sichuan University, Associate Profossor
MAJOR PUBLICATIONS
1) Peng F#, Liao MR#, Qin R#, Zhu S,Peng C, Fu LL, Chen Y, Han B. Regulated cell death (RCD) in cancer: Key pathways and targeted therapies. Signal Transduction Targeted Ther. 2022,7(1):286.
2) Yang AL#, Peng, F#, Zhu LW#, Li X, Ou SL, Huang ZY, Wu S, Peng C*, Liu P*, Kong YA*. Melatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway. 2021,12(8):712
3) Zhang N#, Peng F#, Wang YJ, Yang L, Wu FB, Wang XY, Ye C, Han B, He G. Shikonin induces colorectal carcinoma cells apoptosis and autophagy by targeting galectin-1/JNK signaling axis [J]. Int J of Biol Sci, 2020; 16（1）: 147-161
4) Peng F, Zhang N, Wang CT, Wang XY, Huang W, Peng C, He G, Han B. Aconitine induces cardiomyocyte damage by mitigating BNIP3-dependent mitophagy and the TNF alpha-NLRP3 signalling axis [J]. Cell Proliferat，2020; 53（1）: e12701
5）Wang B#, Peng F#, Huang W, Zhou J, Zhang N, Sheng J, Haruehanroengra P, He G, Han B. Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma [J]. Acta Pharm Sin B, 2020; 10 (8), 1492-1510
6) Wang L, Li S, Fan H, Han M, Xie J, Du J and Peng F. Bifidobacterium lactis combined with Lactobacillus plantarum inhibit glioma growth in mice through modulating PI3K/AKT pathway and gut microbiota. Front. Microbiol. 2022,13:986837.
7) Fan H, Xie X, Kuang X, Du J, Peng F. MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine. American Journal of Chinese Medicine. 2022;50(7):1799-1825.
8) An J, Fan H, Han M, Peng C, Xie J and Peng F Exploring the mechanisms of neurotoxicity caused by fuzi using network pharmacology and molecular docking. Front. Pharmacol. 2022, 13:961012.
9) Zhou J, Wang L, Peng C and Peng F. Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology. Front. Pharmacol. 2022, 13:886198.
10）Peng F, Xiong L, Xie XF, Tang HL,Huang RZ and Peng C. Isoliquiritigenin derivative regulates miR-374a/BAX axis to suppress triple-negative breast cancer tumorigenesis and development [J]. Front Pharmacol, 2020, 11:1-11
